Compare Natera Inc. Common Stock (NTRA) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Wolfspeed Inc — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Wolfspeed Inc trades at $23.6 (market cap $1.30B). The key difference: Natera Inc. Common Stock is far larger — about 43.9× Wolfspeed Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Wolfspeed Inc for 20 Days on average.
| NTRA | WOLF | |
|---|---|---|
Market Cap | $57.03B | $1.30B |
Volume | 1,131,157 | 5,457,662 |
Sector | Health | Technology |
52-Week High | $425.64 | $73.68 |
52-Week Low | $179.42 | $14.80 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $56.18B | $2.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Wolfspeed (WOLF) trades at $28.67, up 2.25% today, amid mixed technical signals with a bearish moving average trend but bullish oscillators. The company shows severe financial strain with negative gross margins of -16.05% and net losses of -$1.61B in 2025, though 2026 projects a return to profitability. Recent news highlights expansion of 200mm silicon carbide technology and ongoing investor litigation investigations.
The stock presents high-risk speculative potential with analyst consensus target of $54.32 suggesting significant upside, but requires successful execution on revenue growth and margin improvement. Key risks include persistent negative profitability, high debt burden, and competitive pressures in the semiconductor materials sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
